A mechanistic review of plumbagin effects against diabetes and obesity

Nurfitri Bustamam¹, Adelina Simamora²,³

¹ Department of Physiology, Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia
² Department of Biochemistry, Faculty of Medicine and Health Sciences, Krida Wacana Christian University, Jakarta, Indonesia
³ Centre for Enzyme Research in Health and Diseases, Krida Wacana Christian University, Jakarta, Indonesia

ABSTRACT

Plumbagin, a plant-derived metabolite, is a naphthoquinone derivative which has been studied for its diverse pharmacological effects including antidiabetic and anti-obesity effects. The present review focuses on reports concerning the effects of plumbagin on diabetes and obesity, and its mechanisms underlying these effects. Plumbagin exerts its antidiabetic effect by modulating key enzymes in glycolysis including α-glucosidase, hexokinase, and aldose reductase, and in gluconeogenesis such as glucose-6-phosphatase and fructose-1,6-biphosphatase. In addition, plumbagin stimulates glucose uptake in skeletal muscle cells by increasing GLUT4 translocation. Plumbagin regulates lipid metabolisms, by inhibiting pancreatic lipase, a lipolytic enzyme. Further, its effect on lipolysis is indicated by an increase in hepatic peroxisome proliferator-activated receptor alpha (PPARα). Regulation of lipogenesis is observed with decrease in sterol regulatory element binding (SREB) in the liver. More mechanistic studies are in need to provide support for the development of plumbagin as a pharmacological-therapeutics for diabetes and obesity.

Keywords:
Antidiabetic, Anti-obesity, Antioxidant, Enzymes, Glycolysis, Lipid-lowering, Plumbagin

1. INTRODUCTION

Diabetes mellitus and obesity remains highly prevalent among different age groups worldwide. Diabetes mellitus is one of the most common metabolic diseases which is characterized by impairment of glucose metabolism. This condition may be caused by defects in insulin secretion and/or cellular insulin resistance in the adipose tissue, the liver, and the skeletal muscles. Obesity is the main risk factor for the development of type 2 diabetes mellitus (T2DM). Obesity is associated with systemic inflammation leading to insulin resistance. Diabetes and obesity are considered significant risk factors in the development of cardio vascular disease, which is the first leading cause of mortality worldwide. Report from International Diabetes Federation showed that 463 million people suffered from diabetes in 2019. This number is projected to increase to 578 million by 2030. Globally, the prevalence of obesity among adults (>18 years old) in 2014 were 11% of men and 15% of women of the world population. Diabetes has become financial burden for individuals, their families, and ultimately national economies. Health spending on diabetes reached USD 760 billion in 2019 worldwide and is estimated to grow to USD 845 billion by 2045. Obesity imposes global economic burden, reaching USD 2.0 trillion in 2014 or 2.8% of global gross domestic products (GDP). These data represent significant health challenge of diabetes and obesity.

Plants remain the primary source for the discovery and development of antidiabetic and anti-obesity agents. Studies related to pure compounds of plant origin have shown promising responses against diabetes and obesity. Plumbagin is one of naphthoquinone derivatives of which are arguably the largest plant secondary metabolites. Pharmacological studies have indicated that plumbagin and plant extracts containing plumbagin have anticancer, anti-inflammatory, anti-obesity, and anti-diabetic effects.
antioxidant\textsuperscript{19,20} and antimicrobial\textsuperscript{21,22} activities. Literature reported that plumbagin and plant extracts containing plumbagin have shown promising therapeutic effects on diabetes and obesity. This review focuses on reports concerning the effects of plumbagin on diabetes and obesity, based on \textit{in vitro} and \textit{in vivo} studies. In addition, this review discusses the mechanisms underlying these effects.

2. METHODS

Relevant literature in English was retrieved up to February 2021 using electronic databases and search engine, including ScienceDirect, Scopus, and Google Scholar. Keywords used were (Plumbagin or Plumbago) and (“antidiabetic” or “hyperglycemia” or “diabetic” or “diabetes” “hyperlipidemia” or “obesity”). From ScienceDirect and Scopus, 98 and 40 articles were collected respectively, whereas from Google Scholar, 100 articles were collected. Only original articles were taken in the study. Irrelevant and duplication titles were excluded. Nine articles met the criteria and were included in the study.

3. PHYSICOCHEMICAL PROPERTIES OF PLUMBAGIN

Plumbagin (\(\text{C}_{11}\text{H}_{8}\text{O}_{3}\), Mw 188.17 g/mol) is a naphthoquinone derivative, with the IUPAC nomenclature 2-methyl-5-hydroxy-1,4-naphthoquinone. Plumbagin is synthesized via acetate and malonate pathway\textsuperscript{23}. Plumbagin presents in plant families \textit{Plumbaginaceae}, \textit{Ebenaceae}, and \textit{Droseraceae}. It is isolated mainly from the root, stem bark, and leaves as orange needle shaped crystal. In fact, the name plumbagin comes from the genus \textit{Plumbago} from which it was firstly isolated\textsuperscript{24}.

![Figure 1. Plumbagin.](image1)

Study using animal model indicates that the oral bioavailability of plumbagin is 38.7\% in a conscious freely moving rat receiving 100 mg/kg body weight of plumbagin\textsuperscript{25}. The relatively low bioavailability could be due to its lipophilic nature, low solubility in water, and short biological half-life\textsuperscript{26}.

![Figure 2. Effects and metabolic targets of plumbagin for the treatment of diabetes and obesity.](image2)
Table 1. Plumbagin mechanisms as antidiabetic and anti-obesity agents.

<table>
<thead>
<tr>
<th>Upregulation/Stimulation</th>
<th>Effects</th>
<th>Downregulation/Inhibition</th>
<th>Organs/models</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>insulin levels HDL, SOD, catalase, GPx, GR, GST</td>
<td>blood glucose, TC, TG, LDL, TNF-α, IL-6, IL-1β levels</td>
<td>skin, STZ-induced diabetic Wistar albino rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPAR-α mRNA serum HDL, GSH, SOD, catalase</td>
<td>SREBP-1c mRNA, serum fasting glucose, insulin levels, HOMA-IR, serum TG, TC, LDL, VLDL, hepatic TG, cholesterol, FFA, lipid peroxidation in the liver, hepatic TNF-α, IL-6, IL-1β</td>
<td>liver, fructose induced obesity &amp; NAFLD in Wistar rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>insulin levels glycogen synthase hexokinase GLUT4 in skeletal muscle</td>
<td>blood glucose, glycogen phosphorylase, glucose-6-phosphatase, fructose-1,6-bisphosphatase</td>
<td>skeletal muscle, STZ-induced diabetic Wistar albino rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GPx, GSH hexokinase</td>
<td>glucose-6-phosphatase</td>
<td>liver, Wistar albino rats</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOD1 expression in vitro</td>
<td>superoxide dismutase</td>
<td>human kidney-2 cells, STZ induced diabetic C57BL/6J mice</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOD activity in vivo</td>
<td>NADPH oxidase 4 (Nox4) expression in vitro</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HDL/total cholesterol ratio excrete fecal cholesterol &amp; phospholipids</td>
<td>serum cholesterol, LDL, VLDL, cholesterol/phospholipid ratio, TC, TG, phospholipid contents of liver and aorta</td>
<td>liver, aorta, cholesterol feeding induced hyperlipidemic &amp; atherosclerotic in rabbits</td>
<td></td>
<td></td>
</tr>
<tr>
<td>fecal cholesterol excretion</td>
<td>serum TG, cholesterol levels, HMGCoA reductase activity or cholesterologenesis in liver</td>
<td>hyperlipidemic induced in Wistar rats by feeding a high fat diet</td>
<td></td>
<td></td>
</tr>
<tr>
<td>potential free radical scavenging effect</td>
<td>liver content of total lipid, lipid peroxidation</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


4. EFFECTS OF PLUMBA GIN ON DIABETES AND ITS MECHANISMS OF ACTION

Plumbagin and plumbagin rich extracts have been reported to reduce plasma glucose level, increase insulin sensitivity, and improve glucose tolerance in different diabetic animal models. It could be that plumbagin exerts its antidiabetic effect through various mechanisms.

Insulin resistance is one of key predictors in the development of diabetes mellitus, therefore has become an important target of therapy.27,28 Pai et al. (2019) reported that plumbagin administered in fructose induced diabetic rats improved glucose tolerance and reduced insulin resistance. Plumbagin treated groups (0.5 mg/kg and 1 mg/kg body weight) reduced fasting plasma glucose level (5.66 and 5.12 mmol/L), insulin (35.53 and 21.99 mIU/L), and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) (8.96 and 5.54), when compared with diabetic rats (7.64 mmol/L, 62.02 mIU/L, and 21.99, respectively). These findings suggest that plumbagin helps regulate glucose metabolism by improving insulin signaling, as also observed from the activation of glucose transporter type 4 (GLUT4) translocation in the skeletal muscles using animal model by other researchers.29

Glucose uptake into the cells is facilitated by GLUT4 transporters trafficked in the plasma membrane of muscle or fat cells.30 The translocation of intracellular GLUT4 transporters into the membrane is regulated by insulin. Plumbagin at doses of 15 and 30 mg/kg body weight given orally for 28 days exerts antidiabetic...
Inhibition on α-glucosidase delays the liberation of glucose from polysaccharides, thus delays its absorption into the blood circulation. Therefore, α-glucosidase inhibition is an important strategy in modulating postprandial blood glucose level. Plumbagin has been shown to inhibit α-glucosidase with an IC_{50} of 204±1.74 μg/mL, compared to acarbose (IC_{50} of 142.77±1.05 μg/mL). This finding was supported by a docking study of the ligand plumbagin docked to α-glucosidase. In this study, plumbagin was shown to interact with two amino acids of α-glucosidase (GLY-228 and GLU-271), with binding energy affinity of -6.7 kcal, which is acceptable in designing new drugs.

Under normal level of blood glucose, most of cellular glucose is phosphorylated into glucose-6-phosphate (G6P) by hexokinase. Only small amount of glucose enters polyol pathway. However, under hyperglycemic condition, around 30% of the body’s glucose is channeled into the polyol pathway. In this pathway, glucose is reduced into sorbitol (a poly alcohol form) by aldose reductase (AR) in the presence of NADPH. Sorbitol is later oxidized into fructose by sorbitol dehydrogenase. This pathway decreases the level of NADPH, which is required by glutathione reductase to regenerate reduced glutathione (GSH) from GSSG (oxidized form of glutathione). GSH is an endogenous antioxidant. Decreased level of GSH compromises the intracellular antioxidant capacity, resulting in increasing reactive oxygen species (ROS). Elevated level of ROS induces oxidative damage by oxidizing proteins, lipids, and DNA, which is key in the pathogenesis of diabetic complications. Plumbagin was reported to inhibit AR isolated from sheep kidney, with an IC_{50} of 1.05 μM. The Lineweaver-Burk plot revealed a non-competitive inhibition mechanism. By comparing the inhibition activity of plumbagin and other naphtoquinone derivatives, the study indicates that OH-moiety in C5 played a more important role in the inhibition than the methoxy group.

Oxidation of free fatty acids (FFAs) is the primary stimulus of gluconeogenesis in the liver. In hyperglycemia condition, increase of FFA oxidation sends the signal to the liver to increase glucose production. Inhibition of fatty acid oxidation is a potential target in controlling hyperglycemia. Cytochrome P450 enzymes are a family of enzymes involved in catalyzing ω-hydroxylation of fatty acids. Recently, Park et al. reported that P450 4A11 was highly upregulated in mouse liver of diet-induced diabetic mice, and suggested that inhibition of this enzyme improved glucose tolerance and ameliorated hepatic steatosis. In studies using cytochrome P450 4A11 isolated from pooled human liver microsome, plumbagin was shown to inhibit ω-hydroxylation of lauric acid in a concentration dependent manner (IC_{50} 1.7 μM). The Lineweaver-Burk plot indicated a mixed inhibition mode.
5. EFFECTS OF PLUMBAGIN ON OBESITY AND LIPID PROFILES

Obesity is a major risk factor in the development of metabolic syndromes, in particular diabetes mellitus and non-alcoholic fatty liver disease (NAFLD). Plumbagin and plant extracts rich in plumbagin have been proven to prevent obesity in several animal models, such as rats and rabbits induced by high fat diet\textsuperscript{40,41} and rats induced by fructose diet\textsuperscript{42}.

Obese rats treated orally with aqueous extract of \textit{Plumbago zeylanica} roots (20, 40, and 80 mg/kg body weight) for 15 days reduced serum total cholesterol and triglycerides concentrations significantly compared to untreated animals. The results were comparable to treated group with positive controls fenofibrate (20 mg/kg) and atorvastatin (8 mg/kg). In addition, treated groups exhibited a significant a decrease in hepatic lipid levels\textsuperscript{40}. It is noting that HMGCoA reductase activity in the liver remained low, thus preventing cholesterogenesis.

Treatment with plumbagin (30 mg/kg body weight) for 60 days in hyperlipidemic rabbits led to the reduction of serum cholesterol and LDL-cholesterol compared to negative control group. The treatment also prevented accumulation of hepatic cholesterol and triglycerides. Further, plumbagin administration prevented plaque formation in atheromatous rabbits\textsuperscript{41}.

Plumbagin have been reported to improve serum lipid profiles in animal models. Shao et al. (2019) reported that treatment with plumbagin (10 and 20%) in STZ-induced diabetic rats elevated HDL level and decreased serum levels of total cholesterol, triglyceride, and LDL compared to diabetic rats.

In term of the mechanisms of action of plumbagin as anti-obesity agent, plumbagin modulates different lipid and fatty acids metabolic pathways. The metabolism of fatty acids and lipids are regulated by lipogenesis and lipolysis. Various enzymes involved in lipogenesis, \textit{i.e.} fatty acid synthase and diglycerideacyltransferase are regulated by sterol regulatory element binding proteins (SREBPs)\textsuperscript{43}. In lipolysis, the process starts with the hydrolysis of triglycerides into FFAs. FFAs are then translocated into the cells by various transport proteins which are mostly regulated by peroxisome proliferator activated receptors (PPARs)\textsuperscript{44}.

Pai et al. (2019) investigated anti-obesity effect of plumbagin on fructose induced obese rats. Administration of plumbagin at doses of 0.5 and 1 mg/kg body weight for 8 weeks reduced the body weight and serum fasting glucose in the rats. The study found that plumbagin administration decreased free fatty acid concentration in the liver and decreased the concentrations of inflammatory cytokines, including TNF-\(\alpha\) and IL-6. Mitigation of obesity by plumbagin may be due to its modulation on SREBP-1c and PPAR-\(\alpha\). When compared to disease control group, plumbagin also decreased

- Inhibits \(\alpha\)-glucosidase
- Inhibits pancreatic lipase
- Inhibits hexokinase
- Inhibits glucose-6-phosphatase and FBP
- Upregulates cytochrome P450 enzymes
- Ameliorates steatosis
- Down-regulates SREBP
- Unregulates PPAR-\(\alpha\)
- Improves antioxidant status
- Decreases proinflammatory cytokines
- Inhibits HMGCoA reductase
mRNA expression of SREBP-1c, which is a regulator of enzymes involved in lipogenesis. In addition, plumbagin increased mRNA expression of PPAR-α, which is one of target genes for the regulation of enzymes participating in lipolysis.

In contrast, plumbagin was shown to inhibit lipolysis. Study by Pai et al. (2018) showed that plumbagin inhibited porcine pancreatic lipase (IC50 82.08±9.47 μM), an enzyme that involves in the catalytic degradation of triglycerides. Inhibition kinetics study showed that plumbagin inhibited lipase in a mixed type mode. Docking study of the ligand-protein binding showed that plumbagin interacted with pancreatic lipase by noncovalent binding through Ser153 and the carbonyl moiety of the plumbagin. At cellular level, anti-obesity activity of plumbagin may also be accounted due to its ability to inhibit differentiation of adipocyte cells.

6. EFFECTS OF PLUMBAGIN ON DIABETIC COMPLICATIONS

Diabetic chronic wounds are one of the most debilitating complications in diabetes. Prolonged hyperglycemia is known to inhibit cell proliferation and collagen production. Shao et al. (2019) reported that plumbagin (10 and 20%) treated topically on diabetic rats significantly increased wound healing rate, reduced epithelization period, increased total collagen and total protein content. Plumbagin treatment increased the expression of transforming growth factor (TGF-β), which is important in the healing process. In addition, plumbagin treatment decreased inflammatory markers including TNF-α, IL-6, and IL-1β levels. Further, plumbagin downregulated levels of CD68 and CD163 proteins. CD68 and CD163 are glycoproteins which are highly expressed on macrophages in wounds.

Diabetic nephropathy is one of serious complications in diabetics. Plumbagin was found to ameliorate diabetic nephropathy by modulating pathways involving NADPH oxidase 4 (Nox4). Nox4-a prooxidant enzyme was reported to be widely expressed in kidneys in the early stages of diabetic nephropathy. Oxidative stress which is induced in hyperglycemia condition contributes to the kidney hypertrophy, possibly through increased fibronectin expression and activation of myofibroblast induced by TGFβ1. Administration of plumbagin on rat model of diabetic nephropathy proved to block Nox4 expression and down-regulate TGFβ1 expression.

7. PLUMBAGIN AS AN ANTIOXIDANT

Persistent hyperglycemia has been noted to increase oxidative stress. In fact, oxidative stress has been implicated in the onset and complications in diabetes. In diabetic condition, multiple prooxidative pathways are upregulated that contribute to oxidative stress, including advanced glycation end-product (AGE), poly-ol, and protein kinase-C. Shao et al. reported that lipid peroxidation level was increased in diabetic rats. The antioxidant enzymes (SOD, CAT, GPx, GR and GST) levels were also found to be lowered. However, administration of plumbagin (10 and 20%) improved the antioxidant status of the treated groups, compared to untreated group, by increasing the activities of antioxidant enzymes and lowering reactive oxygen species (ROS). This finding correlates well with the reports of other researchers, who revealed plumbagin treatment on diabetic rats increased GSH, SOD, and catalase activities.

8. CONCLUSIONS

To date, the literature confirms the antidiabetic and anti-obesity effects of plumbagin in pre-clinical setting. Plumbagin modulates multiple processes critical in the development of hyperglycemia and obesity. Plumbagin decrease insulin resistance, thus promotes glucose uptake. Plumbagin inhibits glycosylation and prevents gluconeogenesis by modulating key enzymes participating in the pathways. Plumbagin also prevents lipid accumulation in the liver by suppressing lipogenesis. More mechanistic studies of plumbagin are needed to provide clear understanding on molecular targets and signalling pathways contributing to these effects. Further, there is no clinical study to support its use for the treatment of diabetes and obesity in the current practice. Clinical study is important in the development of plumbagin as a therapeutic agent for diabetes and obesity.

9. ACKNOWLEDGEMENT

NB is thankful for the support from Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta. AS acknowledges the support from the Faculty of Medicine and Health Sciences and Centre for Enzyme Research in Health and Diseases, both of Krida Wacana Christian University.

Conflict of Interest
Authors declare no conflicting interest.

Funding
The authors acknowledged the funding support from The Research Institute of Krida Wacana Christian University (Grant number: 20/UKKW/LPPM-FKIK/Lit/ XII/2019).

Ethics approval
None to declare.


